474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

Diwakar Davar; Vincent Ribrag; Clementine Sarkozy; Elena Garralda; Honey Kumar Oberoi; Amitkumar Mehta; Giuseppe Curigliano; Carmen Belli; Jasmine Zain; Alex Herrera; Rachel Sanborn; Ecaterina Dumbrava; Andres Forero-Torres; Stephen Ansell

doi:10.1136/jitc-2021-SITC2021.474

Article info

Regular and Young Investigator Award Abstracts

Clinical Trials In Progress

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

Free

Authors

Diwakar Davar UPMC Hillman Cancer Center, Pittsburgh, PA, USA PubMed articles Google scholar articles
Vincent Ribrag Gustave-Roussy Institute, Villejuif, France PubMed articles Google scholar articles
Clementine Sarkozy Gustave-Roussy Institute, Villejuif, France PubMed articles Google scholar articles
Elena Garralda Vall d’Hebron University Hospital, Barcelona, Spain PubMed articles Google scholar articles
Honey Kumar Oberoi Vall d’Hebron University Hospital, Barcelona, Spain PubMed articles Google scholar articles
Amitkumar Mehta Birmingham Comprehensive Cancer Center, Birmingham, AL, USA PubMed articles Google scholar articles
Giuseppe Curigliano University of Milano and European Institute of Oncology, IRCCS, Milan, Italy PubMed articles Google scholar articles
Carmen Belli European Institute of Oncology, IRCCS, Milan, Italy PubMed articles Google scholar articles
Jasmine Zain City of Hope Medical Center, Duarte, CA, USA PubMed articles Google scholar articles
Alex Herrera City of Hope Medical Center, Duarte, CA, USA PubMed articles Google scholar articles
Rachel Sanborn Providence Cancer Institute, Portland, OR, USA PubMed articles Google scholar articles
Ecaterina Dumbrava MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Andres Forero-Torres Seagen Inc, Seattle, WA, USA PubMed articles Google scholar articles
Stephen Ansell Mayo Clinic, Rochester, MN, USA PubMed articles Google scholar articles

Citation

Davar D, Ribrag V, Sarkozy C, et al

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.474

Publication history

First published November 10, 2021.

Online issue publication

March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password